Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

European stocks subdued as investors flee risk, healthcare stocks weigh

Published 06/06/2017, 06:16 AM
© Reuters. People walk through the lobby of the London Stock Exchange in London
STOXX50
-
BARC
-
ROG
-
LHAG
-
NHY
-
POP
-
VWS
-
MS
-
STOXX
-
7011
-
SX6P
-
SXEP
-
STOXXE
-
SXPP
-
CTEC
-

By Helen Reid

LONDON (Reuters) - European shares extended their fall on Tuesday, with healthcare stocks particularly weak, as a diplomatic spat in the Middle East dented appetite for risky assets across the board.

The pan-European STOXX 600 benchmark (STOXX) dropped 0.4 percent, falling for a second session, while euro zone stocks (STOXXE) and blue-chips (STOXX50E) followed suit.

The greatest downward pull came from healthcare stocks. Swiss drugmaker Roche (S:ROG) fell 4.5 percent after investors were disappointed by findings in its Aphinity study for a key breast cancer treatment.

Analysts at Liberum said they believed the study, which showed a lower than expected measure of improvement in disease free survival with Roche's treatment, could make clinical acceptance more difficult.

Medical products company Convatec (L:CTEC) also fell 4.8 percent after shareholders Nordic Capital and Avista sold 250 million shares, raising 805 million pounds ($1 billion).

A rift in the Middle East between Qatar and neighbours Saudi Arabia, United Arab Emirates, Egypt, and Bahrain caused oil to fall further below $50 a barrel, weighing on commodities-heavy European markets.

In an early sign of Qatar's isolation impacting companies operating there, Norsk Hydro (OL:NHY) fell 1.8 percent after saying exports from the Qatalum aluminum plant in Qatar, a joint venture with Qatar Petroleum, were blocked due to the dispute. The company said it was seeking other routes.

Basic resource stocks (SXPP) fell 0.8 percent, while energy stocks (SXEP) reversed earlier losses to trade 0.4 percent higher.

Utilities (SX6P) were the best-performers as investors fled to safety.

Sell-side enthusiasm on European equities seemed to moderate as Morgan Stanley (NYSE:MS) said positive catalysts for the region were beginning to fade.

"Europe has had a very strong run, and tactically it makes sense to look for a more moderate period for a while," said Morgan Stanley equity strategist Matt Garman.

A stronger euro, which weighs on foreign-earning European companies, diminishes the case for European equities, he said.

"Rarely have the currency and positive equity market performance been correlated, and when they have it has been politics related," Garman added, saying relief after the French elections had been felt across asset classes.

The euro has gained 5.6 percent against the dollar over the past two months, and Morgan Stanley strategists expect it to rise further.

Among the handful of gainers, Vestas Wind (CO:VWS) rose 2.9 percent after MHI Vestas, a joint venture with Mitsubishi Heavy Industries (T:7011), said it was launching a new wind turbine.

Also among top gainers was Lufthansa (DE:LHAG), rising 2.6 percent after the German carrier's CEO said he was optimistic on demand and improving traffic from the United States and Asia.

Spain's troubled Banco Popular (MC:POP) hit another record low in choppy trading after Barclays (LON:BARC) cut its price target on the stock.

The bank's shares have lost more than half their value over fears it could be wound down by regulators if it fails to find a buyer.

© Reuters. People walk through the lobby of the London Stock Exchange in London

($1 = 0.7732 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.